M.D., Ph.D., Assistant Professor, Stanford University School of Medicine
Maximilian Diehn received his Bachelor’s Degree in Biochemical Sciences from Harvard College and his M.D./Ph.D. in Biophysics from Stanford University. He is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. Dr. Diehn’s current research program spans laboratory, translational, and clinical studies. His areas of interest include cancer genomics, stem cell biology, and lung cancer biology. His work has been recognized with a variety of awards, including the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and the NIH Director’s New Innovator Award. His group has developed an ultra sensitive and specific method for detection of circulating tumor DNA called CAPP-Seq. Current work is focused on applying CAPP-Seq to a range of clinical contexts, with an emphasis on tumor heterogeneity and minimal residual disease.
Applications of Circulating Tumor DNA to Guide Treatment Decisions
Circulating tumor DNA (ctDNA) represents a promising biomarker for sensitive, specific, and dynamic detection of disease burden in cancer patients. In this presentation I will discusses using ctDNA as a cancer biomarker, with a particular emphasis on potential applications in patients treated with radiotherapy.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: Recent advancements in engineering, molecular biology, imaging and machine learning are posed to revolutionize radiotherapy and improve the outcome in cancer patients. We will review the growing body of evidence on radiation technology development, imaging-based radiotherapy, prognostic biomarkers of radiosensitivity/radioresistance, and the benefits of combining immunooncology with radiotherapy.